在肺高血压中代谢失调
Rajamma Mathew1,2, Sanda Iacobas3, Jing Huang4
1Department of Pediatrics, New York Medical College, Valhalla, NY 10595, USA.
Current issues in molecular biology
|June 27, 2023
概括
肺动脉高血压 (PAH) 涉及代谢变化,包括改变的葡萄糖运输和糖解. 这项研究揭示了PAH大鼠模型中显著的代谢途径重塑,突出显示了失调是关键的病原性因素.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 病理生理学 病理生理学
背景情况:
- 肺动脉高血压 (PAH) 患病率和死亡率很高,部分原因是代谢问题.
- 之前的工作在PAH模型中确定了特定的基因增加.
研究的目的:
- 为了确定PAH中的代谢放松调节.
- 分析PAH大鼠模型中的基因表达变化.
主要方法:
- 在大鼠中通过缺氧或单氨酸诱导的PAH.
- 使用了西方斑点,免疫光和转录基因数据分析.
- 应用了基因组织物范式进行分析.
主要成果:
- 在PAH模型中确定了Slc2a1,Ngf和Nfe2l2的增加.
- 发现了酸盐循环,酸盐代谢和糖解/葡萄糖生成的显著重塑.
- 在所有模型中,糖解/葡萄糖生成是受影响最多的途径.
- 观察到果糖和曼诺糖代谢发生变化,Pmm1取代Pmm2.
- 检测到参与PAH通道病变的基因的调节.
结论:
- 代谢失调是PAH发病的一个重要因素.
- 在PAH中,特定的代谢途径和基因表达被改变.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
234
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
234
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
270
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
270
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
212
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
212
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
204
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
204
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
197
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
197
Physiological Control of Respiration
2.2K
Introduction
Breathing, a seemingly passive process, is regulated by the respiratory center in the brainstem. This center coordinates the involuntary control of respirations, which means it occurs without conscious effort, ensuring a smooth and uninterrupted pattern.
Regulation of Ventilation
The body maintains ventilation by monitoring levels of carbon dioxide (CO2), oxygen (O2), and hydrogen ion concentration (pH) in the arterial blood. Among these factors, the level of CO2 plays a crucial...
Breathing, a seemingly passive process, is regulated by the respiratory center in the brainstem. This center coordinates the involuntary control of respirations, which means it occurs without conscious effort, ensuring a smooth and uninterrupted pattern.
Regulation of Ventilation
The body maintains ventilation by monitoring levels of carbon dioxide (CO2), oxygen (O2), and hydrogen ion concentration (pH) in the arterial blood. Among these factors, the level of CO2 plays a crucial...
2.2K


